Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Key Points: DPPIV (CD26) is a new specific marker of CML LSC that aids CML diagnostics and the measurement, characterization, and purification of LSC. DPPIV on CML LSC degrades SDF-1 and thereby promotes the niche-escape of LSC, which may contribute to extramedullary myeloproliferation in CML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783 · cited 1×
“The concept of LSC is based on the assumption that only a subset of leukemic cells display long-term self-renewal and thus leukemiapropagating activity.(12-16) This hypothesis has major implications for the development of new curative treatment concepts.”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Stem cell concepts renew cancer research
Dick, J. E. (2008) · Blood · doi:10.1182/blood-2008-08-077941 · Cited by 1,010
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H. Y., Kim, J., Chute, J. P., Rizzieri, D., et al. (2009) · Nature · doi:10.1038/nature07737 · Cited by 869
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769 · cited 2×
“This hypothesis has major implications for the development of new curative treatment concepts.(16-21) In fact, current research focuses on LSC-specific drug targets and novel drugs that can attack and eliminate LSC.”
BackgroundCorbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Giustacchini, A., Thongjuea, S., Barkas, N., Woll, P. S., Povinelli, B. J., Booth, C. A. G., Sopp, P., Norfo, R., Rodriguez-Meira, A., Ashley, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4336 · Cited by 403
Cancer stem cell surface markers on normal stem cells
Kim, W.-T., & Ryu, C. J. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.6.039 · Cited by 332
“CD26 (DPP-4) Dipeptidyl peptidase iv, FDA-approved target Yes Hematopoietic Rare (intestine, kidney, male, female tissues, activated T, B, NK cells) Colorectal, leukemia (73-75)”
BackgroundThe chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
“The CXCL12 ligand and its receptor CXCR4 has been linked to intracellular LYN signaling in LSCs,(89) and the CXCL12/ CXCR4 axis is regulated through CXCL12 cleavage by CD26.(90) Reduced homing capacity of LSCs has also been attributed to alterations of the CXCL12/CXCR4 signaling pathway as a result of increased granul…”
BackgroundSelf-citation
Metadata
- Authors
- Herrmann, H., Sadovnik, I., Cerny-Reiterer, S., Rülicke, T., Stefanzl, G., Willmann, M., Hoermann, G., Bilban, M., Blatt, K., Herndlhofer, S., Mayerhofer, M., Streubel, B., Sperr, W. R., Holyoake, T. L., Mannhalter, C., & Valent, P.
- Affiliations
- Ludwig Boltzmann Institute for Hematology and Oncology (AT)
- Medical University of Vienna (AT)
- Ludwig Boltzmann Cluster Oncology, and
- Institute of Laboratory Animal Science (CN)
- University of Veterinary Medicine Vienna (AT)
- Department of Laboratory Medicine, and
- University of Glasgow (GB)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-06-19
- Volume
- 123
- Issue
- 25
- Pages
- 3951-3962
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1979050260
- Cited by
- 223
- References
- 48
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 17 · 2023: 22 · 2022: 16 · 2021: 29 · 2020: 18 · 2019: 24 · 2018: 19 · 2017: 18 · 2016: 18 · 2015: 17 · 2014: 3
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Funders
- Cancer Research UK (11008, C11074/A11008)
- Austrian Science Fund (#F4704-B20)
- Universität Wien
- Medizinische Universität Wien
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- chronic myeloid leukemia, leukemia stem cells, dipeptidyl peptidase IV, CD26, BCR-ABL1, SDF-1/CXCR4 axis, CD34+CD38- cells, imatinib, DPP-4 inhibitors, stem cell markers
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Animals, Antineoplastic Agents, Benzamides, Female, Humans, Male, Middle Aged, Piperazines, Pyrimidines, Transplantation, Heterologous, Tumor Cells, Cultured, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gene Expression Regulation, Leukemic, Fusion Proteins, bcr-abl, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Dipeptidyl Peptidase 4, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Interleukin Receptor Common gamma Subunit, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood-2013-10-536078
- The paper
- Herrmann, H., Sadovnik, I., Cerny-Reiterer, S., Rülicke, T., Stefanzl, G., Willmann, M., Hoermann, G., Bilban, M., Blatt, K., Herndlhofer, S., Mayerhofer, M., Streubel, B., Sperr, W. R., Holyoake, T. L., Mannhalter, C., & Valent, P. (2014). Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood. https://doi.org/10.1182/blood-2013-10-536078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.